No clinical data could be extracted as the provided text contains only web shop instructions.
Do NT-proBNP and hs-cTnT predict the incidence and prognosis of anthracycline-caused cardiovascular toxicities in Non-Hodgkin's Lymphoma patients?
Elevated NT-proBNP and hs-cTnT levels can predict symptomatic cardiovascular toxicities and poor prognosis in NHL patients receiving anthracyclines.
An NT-proBNP-ER ≥ 2.56 or hs-cTnT ≥ 11.68 ng/L, individually or combined, are significant predictors of symptomatic CVTs. Exceeding these thresholds indicates a poor prognosis in NHL patients treated with anthracyclines.
Su et al. (Thu,) conducted a other in Non-Hodgkin's Lymphoma. NT-proBNP and hscTnT was evaluated. No clinical data could be extracted as the provided text contains only web shop instructions.